Pure Biologics achieves key milestone with successful completion of Phase 0 study for PBA-0405 in cancer treatment

Pure Biologics today announced the successful completion of its Phase 0 clinical study for the novel cancer therapy, PBA-0405.

News

Inquiries

13 September

2023

Development plans to the end of 2024

Pure Biologics summarizes implementation and updates Development Plans through the end of 2024.

PB004 project – efficacy and safety confirmed in in vivo models

31 July

2023

PB004 project – efficacy and safety confirmed in in vivo models

Preclinical proof of concept (PoC) of the ability to inhibit tumor growth in a human tumor model containing a molecular target (ROR-1) for candidate PBA-0405.

Pure Biologics meets terms of investment agreement with ACRX and completes strategic options review

30 May

2023

Pure Biologics meets terms of investment agreement with ACRX and completes strategic options review

The strategic options review process is completed.

PB004 project – lead candidate nominated

13 April

2023

PB004 project – lead candidate nominated

Lead candidate in project PB004 for further preclinical and clinical development - the molecule PBA-0405.

PB003G project – lead candidate nominated

5 April

2023

PB003G project – lead candidate nominated

Lead candidate in project PB004 for further preclinical and clinical development - the molecule PBA-0091.

Zapytanie Ofertowe – 00007/00008_ABM_02/2023

18 December

2023

Zapytanie Ofertowe – 00007/00008_ABM_02/2023

23 November

2023

Zapytanie Ofertowe – 00007/00008_ABM_01/2023

9 October

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/5/20 09.10.2020

17 June

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/4/20 17.06.2020

10 April

2020